← Markets

BioNTech SE

BNTX · NASDAQ

Market closed$91.48$-0.080000 (-0.09%)After hours $87.79 · -4.03%

Key statistics

Previous close$91.56
Open$90.56
Day high$92.07
Day low$90.56
52-week high$124.00
52-week low$79.52
Market cap23.13B
Volume1.11M
Average volume961.90K
P/E ratio-19.80
Forward P/E—
EPS-4.62
Dividend yield0.00%

Market context

Why it moved

BioNTech shares edged slightly lower as investors weighed the impact of Arbutus Biopharma filing three new international lawsuits against BioNTech and Pfizer over lipid nanoparticle (LNP) patent infringement, adding to an already complex legal landscape surrounding the company's core mRNA technology.

InstagramMarketbeatAd Hoc NewsHallrenderMarketbeat

What is happening

Recent company-specific developments and publisher coverage.

July 18, 2026BioNTech closed essentially unchanged on the session, but shares are sliding over 4% in after-hours trading as investors weigh a confluence of headwinds. Arbutus Biopharma and Genevant Sciences (Roivant) escalated patent litigation over lipid nanoparticle technology, filing three new international lawsuits against Pfizer and BioNTech in Canada and at the Unified Patent Court in Europe — emboldened by their recent $178M settlement payout from Moderna. Adding to the pressure, Cathie Wood's Ark Genomic Revolution ETF sold approximately $7.4 million worth of BioNTech shares on July 8, nearly exiting its position entirely.

-0.0874

July 17, 2026BioNTech closed modestly lower as new patent litigation from Arbutus Biopharma and Genevant Sciences — seeking injunctions and damages over lipid nanoparticle technology used in Comirnaty — added legal uncertainty, though markets largely shrugged off the news. Investors continue weighing near-term headwinds, including Ark Invest's near-complete exit from the stock and ongoing operating losses amid cooling vaccine demand, against longer-term catalysts like promising Phase 2 lung cancer data for pumitamig and a $1 billion share buyback signaling management confidence in the stock's undervaluation.

-0.4674

July 15, 2026BioNTech closed up 1.76% in regular trading, though shares are slipping marginally in after-hours as investors digest a mixed narrative: BMO Capital reiterated a Buy rating with a $128 price target, implying roughly 40% upside, while the stock remains down about 5% year-to-date. The day's gains followed recent catalysts — upbeat Phase 2 data for its lung cancer drug pumitamig and a $1 billion share buyback announcement — but sentiment remains cautious as Ark Invest's near-complete exit and concerns over post-pandemic revenue sustainability weigh on the stock.

1.7588

July 15, 2026BioNTech closed modestly higher, edging up amid a broader market rally spurred by a favorable CPI report showing headline inflation at 3.5%. Investor sentiment remains cautious, however, as Ark Invest's Genomic Revolution ETF has nearly completely exited its BNTX position after selling roughly $7.4 million in shares on July 8. Analyst support persists — BMO Capital reiterated a Buy rating with a $128 price target — but the stock faces headwinds from ongoing COVID-19 vaccine revenue normalization and a biotech sector facing a projected 79% Q2 earnings drop per FactSet estimates.

0.3664

July 14, 2026BioNTech closed modestly lower as investors weigh the company's ongoing manufacturing restructuring — including its exit from certain German production sites — against a broadly bullish biotech backdrop. BMO Capital reiterated a Buy rating with a $128 price target, while a widely-followed valuation narrative pegs fair value near $500/share, citing the company's deep oncology pipeline. After hours, shares rebounded roughly 1.6%, nearly recovering the day's loss, as the broader biotech sector remains buoyed by strong M&A sentiment and Goldman Sachs projections of an extended rally.

-1.5521

July 11, 2026BioNTech closed modestly lower and is edging further down in after-hours trading, pressured by a confluence of headwinds including ARK Invest's continued liquidation of its ARKG position — offloading over 122,000 shares across two days — and fresh valuation concerns raised in analyst commentary citing the stock's ~58% five-year decline. Morgan Stanley trimmed its price target to $119 from $126, though maintained its Overweight rating, noting biotech could benefit from falling rates. Adding to the cautious tone, BioNTech is reportedly scouting buyers for its German manufacturing sites, signaling a strategic restructuring that investors are still digesting.

-1.6025

July 9, 2026BioNTech edged lower as ARK Invest's ARKG ETF offloaded over 78,000 shares worth ~$7.4 million on July 8—part of a two-day selling spree totaling more than 122,000 shares—as Cathie Wood rotated capital toward SpaceX. Morgan Stanley maintained its Overweight rating but trimmed its price target to $119 from $126, citing a shifting biopharma landscape. These headwinds come despite a broadly bullish backdrop for biotech, with Jim Cramer calling it 'the hottest group in the market' amid an M&A wave, and the healthcare sector (XLV) posting a 6.6% gain in June alone.

-0.588

July 8, 2026BioNTech closed modestly lower as Morgan Stanley trimmed its price target to $119 from $126 while maintaining its Overweight rating, citing a cautious near-term outlook even as the average analyst target sits around $121. The pullback comes against a broadly bullish biotech backdrop — Jim Cramer recently called biotech "the hottest group in the market" amid an M&A wave — though BioNTech's bull case still hinges on oncology pipeline progress and cost restructuring, including its planned exit from German manufacturing sites, as COVID-19 revenue continues to shrink.

-0.806

Simply Wall Street · July 18, 2026How Investors Are Reacting To BioNTech (BNTX) Expanded Global Patent Suits Targeting Its mRNA COVID-19 VaccinesThe Business Journals · July 16, 2026After $178M payoff from Moderna, Arbutus BioPharma expands patent litigation against Pfizer and BioNTechSeeking Alpha · July 16, 2026Pfizer, BioNTech face global patent suits from Arbutus, Roivant over COVID vaccine techReuters · July 3, 2026BioNTech has held talks with buyers over four German sites set to close, Handelsblatt saysBloomberg.com · June 17, 2026BioNTech Investor Förtsch Says Founders’ Spinout Raises ConcernsInvesting.com · May 21, 2026Bernstein initiates BioNTech stock coverage citing pipeline concernsBarron's · March 16, 2026BioNTech Stock Is a Bargain. Why Its Recent Selloff Is a Buying Opportunity.Investor's Business Daily · March 10, 2026BioNTech Crumbles 22% As Co-Founders Plot Their Exit
Mt Newswire · July 16, 2026Arbutus Biopharma, Genevant sue Pfizer, BioNTech Over Lipid Nanoparticle Patents
Benzinga · July 16, 2026Arbutus Biopharma Announces Filing Of Three International Lawsuits Seeking To Enforce Patents Protecting LNP Technology Against Pfizer, BioNTech And Certain Of Their Affiliates
Benzinga · July 8, 2026Morgan Stanley Maintains Overweight on BioNTech, Lowers Price Target to $119
Mt Newswire · July 8, 2026Morgan Stanley Adjusts Price Target BioNTech to $119 From $126, Maintains Overweight Rating
Mt Newswire · July 3, 2026Update: Market Chatter: BioNTech Said to Scout Potential Buyers for German Sites
Mt Newswire · July 3, 2026Market Chatter: BioNTech Said to Scout Potential Buyers for German Sites
Mt Newswire · June 17, 2026Market Chatter: Moderna Looking to Invest in German Production Sites
Mt Newswire · June 17, 2026Moderna Eyeing German Production Investment With BioNTech Closures, CEO Says

Peers

S&P 500SPX · $7,457.69-1.01%Moderna, Inc.MRNA · $61.82-2.11%argenx SEARGX · $860.55+0.30%Regeneron Pharmaceuticals, Inc.REGN · $676.69-0.33%Vertex Pharmaceuticals IncorporatedVRTX · $485.65-0.08%Alnylam Pharmaceuticals, Inc.ALNY · $267.47-5.54%Genmab A/SGMAB · $28.72-0.90%Incyte CorporationINCY · $117.25+0.51%BioMarin Pharmaceutical Inc.BMRN · $59.59-0.68%Insmed IncorporatedINSM · $108.32+0.80%Revolution Medicines, Inc.RVMD · $186.16+3.90%BeOne Medicines AGONC · $312.02-1.70%